Ken Griffin Gilead Sciences, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $11.5 Million - $14.1 Million	-161,000 Reduced 15.39%	885,300 $64.8 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $27.9 Million - $31.7 Million	-381,000 Reduced 26.69%	1,046,300 $84.8 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $11.3 Million - $12.4 Million	-153,100 Reduced 9.69%	1,427,300 $107 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $9.45 Million - $10.8 Million	124,300 Added 8.54%	1,580,400 $122 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $53.3 Million - $60.7 Million	-688,900 Reduced 32.12%	1,456,100 $121 Million

Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $40.2 Million - $57.7 Million	-644,500 Reduced 23.1%	2,145,000 $184 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $46.8 Million - $53.5 Million	-786,500 Reduced 21.99%	2,789,500 $172 Million

1,884

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $86B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.